加载中
NASDAQHealthcareBiotechnology
最新数据
US$17.33
−US$0.17 · -0.97%
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
前收盘价
US$17.33
−US$0.17 · -0.97%
盘前
US$17.23
−US$0.10 · -0.58%
10月13日 7:05 ET
盘中时间采用ET。市场数据可能有所延迟。
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
日内区间
当前US$17.33
52周区间
当前US$17.33
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
40
偏贵
情绪
55
多空交织
风险
35
中等风险
动量
71
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
日内区间
当前US$17.33
52周区间
当前US$17.33
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|
| 研究与开发 | 1.25亿 USD | 6361.9万 USD | 3061.7万 USD | 3131.2万 USD |
| 销售、一般及管理费用 | 3050.8万 USD | 1877万 USD | 927.2万 USD | 634.4万 USD |
| 营业费用 | 1.56亿 USD | 8238.9万 USD | 3988.9万 USD | 3765.6万 USD |
| 利息收入 | 1787.1万 USD | 1458.1万 USD | 131.4万 USD | 4000 USD |
| 利息支出 | — | — | — | 11.2万 USD |
| 折旧和摊销 | 10.5万 USD | 5.6万 USD | 1.9万 USD | 1万 USD |
| 营业利润 | −1.56亿 USD | −8238.9万 USD | −3988.9万 USD | −3765.6万 USD |
| 净利润 | −1.38亿 USD | −6799.5万 USD | −5198.5万 USD | −3784.5万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$32.57
上涨空间 87.94%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3876.42万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM2018.98万0.03%787.4亿 USD0.19%US$277.9-0.37%
State Street SPDR S&P Biotech ETFXBI1881.72万0.19%103.03亿 USD0.35%US$151.4-1.54%
Vanguard Extended Market ETFVXF1148.01万0.01%954亿 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO620.73万0.04%139.17亿 USD0.24%US$353.71-0.86%
iShares Biotechnology ETFIBB589.55万0.05%108.2亿 USD0.44%US$204.26-1.08%
Vanguard Russell 2000 ETFVTWO587.11万0.03%180亿 USD0.06%US$112.27-0.35%
Dimensional - US Small Cap ETFDFAS462.5万0.01%338.04亿 USD0.31%US$78.17-0.23%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
